Mitral regurgitation (MR) is one of the most prevalent valve disorders and has numerous etiologies, including primary (organic) MR, due to underlying degenerative/structural mitral valve (MV) pathology, and secondary (functional) MR, which is principally caused by global or regional left ventricular remodeling and/or severe left atrial dilation. Diagnosis and optimal management of MR requires integration of valve disease and heart failure specialists, MV cardiac surgeons, interventional cardiologists with expertise in structural heart disease, and imaging experts. The introduction of transcatheter MV therapies has highlighted the need for a consensus approach to pragmatic clinical trial design and uniform endpoint definitions to evaluate outcomes in patients with MR. The Mitral Valve Academic Research Consortium is a collaboration between leading academic research organizations and physician-scientists specializing in MV disease from the United States and Europe. Three in-person meetings were held in Virginia and New York during which 44 heart failure, valve, and imaging experts, MV surgeons and interventional cardiologists, clinical trial specialists and statisticians, and representatives from the U.S. Food and Drug Administration considered all aspects of MV pathophysiology, prognosis, and therapies, culminating in a 2-part document describing consensus recommendations for clinical trial design (Part 1) and endpoint definitions (Part 2) to guide evaluation of transcatheter and surgical therapies for MR.
have exposed the complexities required to properly evaluate MR therapies, specifically regarding the appropriate study population and control group, background medications and procedures, efficacy and safety endpoints, learning curve issues, and analysis cohort and statistical considerations (8, 9) . Moreover, although the outcomes of patients with MV disorders are sometimes tracked at single centers (10, 11) or in national databases (12, 13) (15) (16) (17) , as well as bleeding definitions (18) , and have been adopted to improve the uniformity and interpretation of clinical studies (19) For U.S. approval trials, depending on the comparator group, either a superiority or noninferiority design for the primary endpoint may be appropriate.
Although superiority in either safety and/or effectiveness is typically preferred for FDA regulatory approval, a new device may demonstrate noninferiority for both and still be approvable as an alternative therapy to the existing standard of care, depending on the benefit-risk balance. In studies addressing an unmet clinical need for a severe disease in which the available therapeutic alternatives are suboptimal, the benefit-risk profile of an investigational device may also be favorable even if effectiveness is somewhat less than that of the comparator if treatment with the investigational device shows evidence of substantial safety benefits (and is more effective than a putative placebo) (20) . As knowledge accumulates and technology matures, noninferiority designs (e.g., comparing a new design to a previously approved transcatheter device) and even nonrandomized comparisons to performance goals or objective performance criteria may become reasonable to evaluate device iterations and to expand the indications for use (label expansion) of existing approved devices.
Primary effectiveness should be evaluated with a clinically relevant endpoint, either a single event type (e.g., hospitalization for heart failure) or a composite measure (e.g., death or hospitalization for heart failure). Additional support for effectiveness can be obtained through the use of validated instruments demonstrating improved quality-of-life, improvement in symptom status (e.g., New York Heart Association [NYHA] functional classification), and improved exercise performance. Although at the increasing attention is being paid to patient-centered benefit-risk metrics in device approval decisions.
Evidence of meaningful MR reduction by the device that is sustained over time is important to demonstrate, and improvement in ventricular volumes and function during follow-up are additional supportive secondary effectiveness endpoints that should be assessed. Safety assessments may include both shortand long-term procedural and device-related complications, and a primary safety endpoint (separate from the primary effectiveness endpoint) should be pre-specified (see Primary and Secondary Endpoints).
Finally, the duration of follow-up must be sufficient to ensure adequate device durability, relevant to the population being studied and comparable to alternative therapies, if available. Late device failures may occur after the primary endpoint of pre-market studies, necessitating robust post-market surveillance to monitor long-term device performance after regulatory approval.
Identifying the intended population for use (e.g., primary vs. secondary MR, high vs. low surgical risk, and so on) may importantly affect decisions on comparator therapies (e.g., medical, surgical, or other transcatheter devices; see Control Group Therapies).
As a general principle, because the pathophysiology, prognosis, control groups, and response to therapies for primary and secondary MR vary greatly, these 2 conditions should be studied in separate investigations unless randomization is stratified and each cohort is individually powered for both safety and effectiveness. As a corollary, inclusion and exclusion criteria must be carefully selected to define For both randomized trials and registry studies of MR therapies, written informed consent must be obtained from all patients unless waivers are provided with specific ethical oversight. Within the framework of a randomized trial, study-eligible patients who decline randomization should ideally be followed in a separate registry to provide additional insights into potential study selection bias and the natural history of the control population. If exploratory comparison with randomized trial arms is contemplated, the statistical methodology must be pre-specified and justified (e.g., propensity scoring analysis with appropriate covariates, and so on).
Finally, although randomized trials with primary clinical endpoints are strongly recommended, given the logistical, time and cost constraints, MVARC acknowledges that many investigations of MV therapeutics will collect observational or registry data only (preferably compared with either a concurrent or historical control group), or if randomized, will not be powered for clinical endpoints. Potential efficacy endpoints for these studies may include reduction in MR grade, improvement in LV pressures and chamber dimensions, improved quality of life, and enhanced functional capacity (see Primary and Secondary Endpoints). However, currently none of these endpoints have been sufficiently linked to a major clinical outcome such as death or heart failure hospitalization to be considered a true surrogate, especially as procedural risks must be taken into account when considering the benefit-risk profile of a novel therapy.
As such, these studies should be considered hypoth- The mechanism of MR may be described by Carpentier's classification of leaflet motion: type I: normal leaflet motion (e.g., annular dilation, leaflet perforation, or clefts), type II: excessive leaflet motion (e.g., chordal elongation or rupture), and type III: restricted leaflet motion ( Figure 1) When feasible, the vena contracta width and the (42) . #In secondary MR, LV and LA size and PAP may be increased by the underlying LV systolic and diastolic dysfunction and, therefore, may be increased in all grades of MR.
PAP ¼ pulmonary artery pressure; PISA ¼ proximal isovelocity surface area; other abbreviations as in Table 2 . Although it may not be possible to always prevent Stone et al. 
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From a 3-dimensional (3D) volume of the heart, the volume of interest is positioned at the atrioventricular level including the systolic excursion of the mitral annulus.
The volume is then reformatted in 2-chamber (2CH) and 4-chamber (4CH) views, and the transmitral flow is quantified from the 3D velocity vector field. During diastole, the mitral inflow is acquired, and in systole, the regurgitant flow can be identified. Through-plane motion correction is performed from the longitudinal velocity recommendations for control groups in MR trials appear in Table 6 . Table 7 details numerous considerations for inclusion and exclusion criteria for investigational MR trials that may be used as a framework. Although each trial will need to tailor these criteria to the specific device and patient population being studied, general principles may be applied when selecting patients with primary and secondary MR for enrollment in MV trials.
INCLUSION AND EXCLUSION CRITERIA
RISK SCORES AND SURGICAL CANDIDACY. A major decision point that must be reached early is whether the patient is an acceptable surgical candidate. Food and Drug Administration guidelines, patients with primary mitral regurgitation should be determined to be at "prohibitive surgical risk" for GDMT or approved transcatheter devices to be considered as an acceptable control group in regulatory trials. ‡In patients for whom the local standard of care for secondary mitral regurgitation is not surgical mitral valve repair or replacement. Mitral valve repair or replacement might also be a suitable control group for selected patients in whom the local standard of care for secondary mitral regurgitation is mitral valve surgery, depending on the experimental device characteristics (e.g., for studies of transcatheter mitral valve replacement).
GDMT ¼ guideline-directed medical therapy.
Stone et al. Life expectancy <1 yr due to noncardiac conditions NYHA functional class IVb or ACC/AHA stage D heart failure Hypotension (systolic pressure <90 mm Hg) or requirement for inotropic support or mechanical hemodynamic support UNOS status 1 heart transplantation or prior orthotopic heart transplantation Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or any other structural heart disease causing heart failure other than dilated cardiomyopathy of either ischemic or nonischemic etiology Fixed pulmonary artery systolic pressure >70 mm Hgk Physical evidence of right-sided congestive heart failure with echocardiographic evidence of moderate or severe right ventricular dysfunction. Mitral valve anatomy which may preclude proper device treatment Mitral valve area <4.0 cm 2 (if new device therapy may further decrease the mitral orifice area) Any prior mitral valve surgery or transcatheter mitral valve procedure Stroke or transient ischemic event within 30 days before randomization Modified Rankin Scale $4 disability TAVR within 1 month before randomization Severe symptomatic carotid stenosis (>70% by ultrasound). Need for emergent or urgent surgery for any reason or any planned cardiac surgery within the next 12 months Absence of CRT with Class I indication criteria for biventricular pacing Implant or revision of any rhythm management device (CRT or CRT-D) or implantable cardioverter-defibrillator within 1 month before randomization Untreated clinically significant coronary artery disease requiring revascularization Any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid surgery within 30 days Tricuspid valve disease requiring surgery or severe tricuspid regurgitation Aortic valve disease requiring surgery Need for any cardiovascular surgery (other than for MV disease) Echocardiographic evidence of intracardiac mass, thrombus, or vegetation Active endocarditis Active infections requiring current antibiotic therapy Subjects in whom transesophageal echocardiography is contraindicated or high risk Any condition making it unlikely the patient will be able to complete all protocol procedures (including compliance with guideline directed medical therapy) and follow-up visits Patient (or legal guardian) unable or unwilling to provide written, informed consent before study enrollment *Ideally as assessed by an independent echocardiographic core laboratory. Different quantitative criteria may apply for primary and secondary MR. See Assessment of Mitral regurgitation: Role of Noninvasive Imaging. †As a starting point for consideration. The upper limit of LVEF should be selected to ensure inclusion of patients with true secondary MR due to LV dysfunction. By unloading the LV, severe MR increases the LVEF, and LVEF #60% is consistent with LV dysfunction; however, lowering the upper limit of the LVEF range (e.g., to #50%) may be considered to increase specificity. Similarly, the lower level of LVEF should be selected to ensure exclusion of patients who might not be capable of benefitting from MR reduction. An acute increase in afterload by reducing or eliminating MR may also (rarely) result in hemodynamic compromise in the early postintervention period. In general, a lower limit LVEF of 20% is recommended. Lower and upper limits for LV dimensions should also be considered on the basis of the specific device being tested. ‡In the case of secondary MR, if patients with both ischemic and nonischemic dilated cardiomyopathy are enrolled, randomization should be stratified by this variable. §As a starting point for consideration. Patients should be symptomatic, and most patients should be ambulatory (able to complete a 6-min walk test). Dedicated trials, however, may be designed for asymptomatic or end-stage patients. kAssessed by echocardiography or right heart catheterization, unless active vasodilator therapy in the catheterization laboratory is able to reduce the pulmonary vascular resistance to <3 Wood Units or between 3 and 4.5 Wood Units, with v-wave less than twice the mean of the pulmonary capillary wedge pressure. 
Involvement of experts in neurocognitive dysfunction
(e.g., geriatricians, neurologists) with serial evaluations pre-and post-procedure is essential for meaningful appraisal; however, it should be acknowledged that evaluation and collection of frailty parameters can be time consuming and resource intensive.
Further research is required to determine the extent to which frailty assessments should be a routine part of MV clinical trials and registries. Severe procedure-specific impediment *Use of the STS predicted risk of mortality (PROM) to predict risk in a given institution with reasonable reliability is appropriate only if institutional outcomes are within 1 SD of STS average observed/expected ratio for the procedure in question. †Seven frailty indexes: Katz Activities of Daily Living (independence in feeding, bathing, dressing, transferring, toileting and urinary continence) and independence in ambulation (no walking aid or assist required for 5-m walk in <6 s). Other scoring systems can be applied to calculate no, mild, or moderate-to-severe frailty. ‡Examples of major organ system compromise: Cardiac: severe LV systolic or diastolic dysfunction or RV dysfunction, or fixed pulmonary hypertension; CKD stage 3 or worse; pulmonary dysfunction with FEV1 <50% or DLCO2 <50% of predicted; CNS dysfunction: dementia, Alzheimer's disease, Parkinson's disease, or CVA with persistent physical limitation; GI dysfunction: Crohn's disease, ulcerative colitis, nutritional impairment, or serum albumin <3.0; cancer: active malignancy; and liver: any history of cirrhosis, variceal bleeding, or elevated INR in the absence of VKA therapy. §Examples: tracheostomy present, heavily calcified ascending aorta, chest malformation, arterial coronary graft adherent to posterior chest wall, or radiation damage. Adapted with permission from Nishimura et al. (1) . The primary and secondary endpoints should be selected such that meeting these endpoints will demonstrate reasonable assurance of safety and effectiveness and a favorable benefit-risk profile.
PRIMARY AND SECONDARY ENDPOINTS
All endpoints must be well defined such that they PRIMARY ENDPOINTS. Clinically meaningful effectiveness measures to be considered for MR device therapies are presented in Table 9 . All-cause mortality should be incorporated into the primary efficacy measures of functional performance are presented in Table 9 . Such measures might be regarded as having 
ANALYSIS OF PRIMARY AND SECONDARY ENDPOINTS.
It is recommended that primary and secondary endpoints be assessed at the intervals noted in Table 11 .
In most MR trials, the primary effectiveness endpoint should be assessed no sooner than 1 year after randomization, whereas the primary safety endpoint may be assessed as soon as 30 days after randomization to account for procedural complications (each taking into account between group differences in time from randomization to treatment initiation).
Depending on the device, however, follow-up longer than 30 days may be appropriate for the primary safety endpoint assessment. 
ROLE OF THE CENTRAL ELIGIBILITY COMMITTEE
Even with the use of local heart teams and detailed protocol inclusion/exclusion criteria, site-based variability in patient selection for studies of devices treating MR remains a concern. To enhance interpretability, particularly for regulatory trials of novel MR devices, it is strongly recommended that each patient be presented to a central eligibility committee for evaluation of patient appropriateness for enrollment. The central eligibility committee serves multiple important functions ( Table 12 ). The members of the central eligibility committee for MR trials should include at a minimum a moderator, a heart failure specialist, and an experienced MV surgeon.
Each patient should be presented to the committee by Tables 2 and 3 The MV surgeon (and others) on the central eligibility committee may, however, query the local surgeon as to his/her criteria for operability to ensure, for example, that crossover to surgery will not be considered should the patient be randomized to a nonsurgical therapy (unless permitted by the protocol). Purpose To ensure that key eligibility criteria are met before enrollment into a clinical trial. For example (depending on the trial): to ensure the patient is appropriately symptomatic to ensure the appropriate severity of MR, left ventricular function, and chamber size are present* to ensure the patient is treated and is adherent with optimal guidelinedirected medical therapy for heart failure, including maximally tolerated doses of each indicated class of medication to ensure the patient does not require additional (non-mitral valve) cardiac surgery, coronary revascularization or ICD/CRT therapy Composition Depends on the specific study, but in general consists of: moderator (voting or nonvoting; may also serve 1 of the following roles) heart failure specialist (voting) high-volume MV cardiac surgeon (voting) AE MV cardiologist (voting) AE interventional cardiologist experienced in MV procedures (voting) Sponsor may be present (nonvoting)
STATISTICAL CONSIDERATIONS

Presenting physicians
Members of the local heart team, including at a minimum (depending on the trial): local principal investigator heart failure specialist and/or valve cardiologist MV cardiac surgeon Format Web-based telephone calls at which original source documents are reviewed (clinical data, medications, laboratory results, echocardiograms, electrocardiograms, and so on). Detailed notes are taken. After patient review, a vote is held and recorded.
Outcome
Patients will be approved, denied, or deferred *Ideally determined by echocardiographic core laboratory review of the qualifying imaging studies before the central eligibility committee meeting.
CRT ¼ cardiac resynchronization therapy; ICD ¼ implantable cardioverter-defibrillator; other abbreviations as in Table 2 .
N o n f a t a l t i m e -r e l a t e d e v e n t s . Nonfatal events can repeat (e.g., stroke, rehospitalization). All occurrences should be analyzed, not just time to first occurrence, using the Nelson (90), Andersen-Gill (91), or other estimators (92) . These methods make different assumptions with respect to the independence of events, hazard function after each occurrence, and informativeness of death and other competing risks (93) .
W e i g h t e d e v e n t s . Although generally not done, consideration may be given to weighing nonfatal events (e.g., by applying the National Institutes of Health stroke scale and considering the duration and cost of rehospitalization), which may be further analyzed as cumulative functions, a common industrial method when considering costs (90, 94, 95) . KEY WORDS heart failure, mitral regurgitation, mitral valve, valve intervention, valve surgery (or cardiac surgery) APPENDIX For complete information on the MVARC members and participants, please see the online version of this article.
